Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Subtypes in BRCA-mutated breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. CD3 immunohistochemical staining in diagnosis of lymphocytic colitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Observer variability in the histopathologic diagnosis of microscopic colitis and subgroups

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exploring the hereditary background of renal cancer in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genomisk medicin til præimplantations-, 
præ- og postnatal diagnostik

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Toward mechanistic models for genotype-phenotype correlations in phenylketonuria using protein stability calculations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Approximately 3-5% of breast cancer patients are BRCA1- or BRCA2 germ-line mutation carriers. In this study we correlated the distribution of intrinsic molecular subtypes according to failure pattern in a Danish cohort of BRCA germ-line mutated breast cancer patients. Tumor tissue from 425 BRCA germ-line mutated breast cancer patients were analyzed by immunohistochemistry (IHC) for hormone receptor status, proliferation index (Ki67) and HER2. Surrogate intrinsic molecular subtypes were assigned according to approximated St. Gallen criteria. Annual hazard rates (AHR) were calculated for death and local- or distant relapse, contralateral breast cancer, new primary cancer other than breast cancer, or death as first event (disease-free event). Luminal A-like subtype was observed with a frequency of 9% and 35% for BRCA1 and BRCA2, respectively and, for both BRCA1 and BRCA2 patients, the luminal B-like subtype was more frequent than the luminal A-like subtype (BRCA1 21% and BRCA2 40% luminal B-like). No events or deaths were observed for luminal A-like subtype during the first 2.5years and 0-5years, respectively. AHR for luminal B-like tumors was 5.34% (95% CI=1.49-1.19) and 1.76% (95% CI=0.36-3.16) for disease-free event and death, respectively, and for basal-like 6.58% (95% CI=2.98-10.18) and 4.54% (95% CI=2.69-6.40). A substantial proportion of BRCA carriers had luminal A-like subtype, and these were mainly BRCA2 carriers. Luminal A-like subtype was significantly associated with low AHR the first five years after surgery. This study warrants further exploration of the impact of the molecular intrinsic subtypes on survival in BRCA-mutated breast cancer patients.

OriginalsprogEngelsk
TidsskriftHuman Pathology
Vol/bind84
Sider (fra-til)192-201
Antal sider10
ISSN0046-8177
DOI
StatusUdgivet - feb. 2019

ID: 55905574